Navidea Biopharmaceuticals (NAVB) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 07, 2020
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000810509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		25,845,972
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 1,617,001	$ 1,047,159
Stock subscriptions and other receivables	4,037,187	901,339
Prepaid expenses and other	411,834	967,285
Total current assets	6,066,022	2,915,783
Property and equipment	1,215,944	1,207,537
Less accumulated depreciation and amortization	1,195,167	1,177,327
Property and equipment, net	20,777	30,210
Right-of-use lease assets	458,280	404,594
Less accumulated amortization	148,011	122,906
Right-of-use lease assets, net	310,269	281,688
License agreements, patents and trademarks	593,942	478,672
Less accumulated amortization	111,519	93,259
License agreements, patents and trademarks, net	482,423	385,413
Other assets	227,192	537,812
Total assets	7,106,683	4,150,906
Current liabilities:
Accounts payable	1,160,911	1,112,069
Accrued liabilities and other	2,296,544	2,150,974
Notes payable	410,254	305,955
Lease liabilities, current	277,365	250,553
Total current liabilities	4,145,074	3,819,551
Lease liabilities	434,324	512,344
Deferred revenue	700,000	700,000
Total liabilities	5,279,398	5,031,895
Commitments and contingencies (Note 10)
Stockholders’ deficit:
Common stock; $.001 par value; 300,000,000 shares authorized; 24,547,961 and 19,234,960 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	215,545	210,232
Common stock subscribed; $.001 par value, 461,729 and 902,162 shares subscribed as of June 30, 2020 and December 31, 2019, respectively	462	902
Additional paid-in capital	350,178,082	345,847,676
Accumulated deficit	(352,748,108)	(347,671,102)
Total Navidea stockholders' deficit	(2,354,019)	(1,612,292)
Noncontrolling interest	731,304	731,303
Total stockholders’ deficit	(1,622,715)	(880,989)
Total liabilities, mezzanine equity and stockholders’ deficit	7,106,683	4,150,906
Series C Preferred Stock [Member]
Mezzanine equity:
Series C preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding as of June 30, 2020 and December 31, 2019, respectively
Series C preferred stock subscribed; $.001 par value, 350,000 and 0 shares subscribed as of June 30, 2020 and December 31, 2019, respectively	3,450,000
Total mezzanine equity	$ 3,450,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	24,547,961	19,234,960
Common stock, shares outstanding (in shares)	24,547,961	19,234,960
Common stock subscription, shares authorized (in shares)	461,729	902,162
Series C Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, par value, ssubscribed (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares subscribed (in shares)	350,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue from contract with customer		$ 9,000	$ 16,000	$ 24,000	$ 30,000
Grant and other revenue		262,181	244,199	403,232	282,673
Total revenue		271,101	260,092	427,373	301,716
Cost of revenue		357	238	966	6,364
Gross profit		270,744	259,854	426,407	295,352
Operating expenses:
Research and development		1,281,779	1,070,642	2,281,048	1,811,225
Selling, general and administrative		1,329,591	1,861,600	3,157,345	3,590,116
Total operating expenses		2,611,370	2,932,242	5,438,393	5,401,341
Loss from operations	[1]	(2,340,626)	(2,672,388)	(5,011,986)	(5,105,989)
Other income (expense):
Interest income, net		15,343	1,630	12,971	11,478
Other, net		(336)	(3,220)	(212)	(4,356)
Total other income (expense), net	[2]	15,007	(1,590)	12,759	7,122
Loss before income taxes		(2,325,619)	(2,673,978)	(4,999,227)	(5,098,867)
Benefit from (provision for) income taxes			168		(708)
Loss from continuing operations		(2,325,619)	(2,673,810)	(4,999,227)	(5,099,575)
Income (loss) from discontinued operations, net of tax effect			632		(2,665)
Net loss		(2,325,619)	(2,673,178)	(4,999,227)	(5,102,240)
Less (loss) income attributable to noncontrolling interest		(1)	(3)	1	(15)
Deemed dividend on Series C Preferred Stock beneficial conversion feature		(77,778)		(77,778)
Net loss attributable to common stockholders		$ (2,403,396)	$ (2,673,175)	$ (5,077,006)	$ (5,102,225)
Loss per common share (basic and diluted):
Continuing operations (in dollars per share)		$ (0.11)	$ (0.24)	$ (0.24)	$ (0.48)
Attributable to common stockholders (in dollars per share)		$ (0.11)	$ (0.24)	$ (0.24)	$ (0.48)
Weighted average shares outstanding (in shares)		22,759,393	11,096,834	21,481,514	10,560,265
Royalty [Member]
Revenue from contract with customer		$ 8,920	$ 5,940	$ 24,141	$ 9,090
License [Member]
Revenue from contract with customer			$ 9,953		$ 9,953
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Net loss	$ (2,325,619)	$ (2,673,608)	$ (2,673,178)	$ (2,429,061)	$ (4,999,227)	$ (5,102,240)
Unrealized (loss) gain on available-for-sale securities			(40)	958		918
Comprehensive loss	$ (2,325,619)	$ (2,673,608)	$ (2,673,218)	$ (2,428,103)	$ (4,999,227)	$ (5,101,322)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)	AOCI Attributable to Parent [Member]	Preferred Stock [Member]Private Placement [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Registered Direct Offering [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Registered Direct Offering [Member]	Common Stock [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Common Stock [Member]	Common Stock Subscription [Member]Private Placement [Member]	Common Stock Subscription [Member]Registered Direct Offering [Member]	Common Stock Subscription [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member]Private Placement [Member]	Common Stock Subscriptions Receivable [Member]Registered Direct Offering [Member]	Common Stock Subscriptions Receivable [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Common Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Registered Direct Offering [Member]	Additional Paid-in Capital [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]Registered Direct Offering [Member]	Retained Earnings [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]Private Placement [Member]	Noncontrolling Interest [Member]Registered Direct Offering [Member]	Noncontrolling Interest [Member]Conversion from Series C Preferred Stock To Common Stock [Member]	Noncontrolling Interest [Member]	Private Placement [Member]	Registered Direct Offering [Member]	Conversion from Series C Preferred Stock To Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018								10,019,535
Balance at Dec. 31, 2018	$ (730)							$ 200,391												$ 338,265,383				$ (336,722,905)				$ 668,321				$ 2,410,460
Stock issued (in shares)								17,857
Stock Issued								$ 357												49,643												50,000
Stock compensation expense																				61,978												61,978
Net loss																								(2,429,049)				(12)				(2,429,061)
Total comprehensive income (loss)																																(2,428,103)
Issued restricted stock								$ 300																								300
Balance (in shares) at Mar. 31, 2019								10,052,392
Balance at Mar. 31, 2019	228							$ 201,048												338,377,004				(339,151,954)				668,309				94,635
Issued restricted stock (in shares)								15,000
Issued restricted stock								$ 300																								300
Unrealized (loss) gain on available-for-sale securities	958																															958
Balance (in shares) at Dec. 31, 2018								10,019,535
Balance at Dec. 31, 2018	(730)							$ 200,391												338,265,383				(336,722,905)				668,321				$ 2,410,460
Issued stock in payment of employee bonuses (in shares)																																8,128
Net loss																																$ (5,102,240)
Total comprehensive income (loss)																																(5,101,322)
Balance (in shares) at Jun. 30, 2019								18,059,406
Balance at Jun. 30, 2019	188							$ 209,056												343,879,087				(341,825,130)				668,306				2,931,507
Unrealized (loss) gain on available-for-sale securities																																918
Balance (in shares) at Mar. 31, 2019								10,052,392
Balance at Mar. 31, 2019	228							$ 201,048												338,377,004				(339,151,954)				668,309				94,635
Stock issued (in shares)								8,000,000
Stock Issued								$ 8,000												5,158,441												5,166,441
Stock compensation expense																				66,159												66,159
Net loss																								(2,673,176)				(3)				(2,673,178)
Total comprehensive income (loss)																																(2,673,218)
Issued stock to 401(k) plan (in shares)								8,128
Issued stock to 401(k) plan								$ 8												19,580												19,588
Balance (in shares) at Jun. 30, 2019								18,059,406
Balance at Jun. 30, 2019	188							$ 209,056												343,879,087				(341,825,130)				668,306				2,931,507
Unrealized (loss) gain on available-for-sale securities	$ (40)																															(40)
Rounding adjustments related to reverse stock split (in shares)								(1,114)
Rounding adjustments related to reverse stock split																				(3,385)												(3,385)
Issued stock to 401(k) plan (in shares)								8,128
Value of warrants issued in connection with public offering																				261,288												841,559
Balance (in shares) at Dec. 31, 2019								19,234,960				902,162
Balance at Dec. 31, 2019								$ 210,232				$ 902								345,847,676				(347,671,102)				731,303				(880,989)
Issued stock in payment of services (in shares)								3,810
Issued stock in payment of services								$ 4												4,797												4,801
Issued stock in payment of employee bonuses (in shares)								53,315
Issued stock in payment of employee bonuses								$ 53												64,458												64,511
Stock issued (in shares)					902,162	1,000,001			(902,162)
Stock Issued					$ 902	$ 1,000			$ (902)									$ 699,000												$ 700,000
Stock subscribed (in shares)									2,373,529	647,058
Stock subscribed									$ 2,374	$ 647			(912,500)				2,015,126	549,353											1,105,000	550,000
Stock compensation expense																				39,246												39,246
Net loss																								(2,673,610)				2				(2,673,608)
Total comprehensive income (loss)																																(2,673,608)
Balance (in shares) at Mar. 31, 2020								21,194,248				3,020,587
Balance at Mar. 31, 2020								$ 212,191				$ 3,021				(912,500)				349,219,656				(350,344,712)				731,305				(1,091,039)
Balance (in shares) at Dec. 31, 2019								19,234,960				902,162
Balance at Dec. 31, 2019								$ 210,232				$ 902								345,847,676				(347,671,102)				731,303				$ (880,989)
Issued stock in payment of employee bonuses (in shares)																																32,651
Net loss																																$ (4,999,227)
Total comprehensive income (loss)																																$ (4,999,227)
Issued stock to 401(k) plan (in shares)																																94,159
Issued stock to 401(k) plan																																$ 172,000
Balance (in shares) at Jun. 30, 2020								24,547,961				461,729
Balance at Jun. 30, 2020								$ 215,545				$ 462								350,178,082				(352,748,108)				731,304				(1,622,715)
Unrealized (loss) gain on available-for-sale securities
Issued stock to 401(k) plan (in shares)																																94,159
Balance (in shares) at Mar. 31, 2020								21,194,248				3,020,587
Balance at Mar. 31, 2020								$ 212,191				$ 3,021				(912,500)				349,219,656				(350,344,712)				731,305				$ (1,091,039)
Issued stock in payment of employee bonuses (in shares)								40,844
Issued stock in payment of employee bonuses								$ 41												106,970												107,011
Stock issued (in shares)				70,000	1,911,800	647,058			(1,911,800)	(647,058)
Stock Issued				$ 70	$ 1,912	$ 647			$ (1,912)	$ (647)			520,030						$ 699,930										520,030		$ 700,000
Stock subscribed													$ 392,470																$ 392,470
Stock compensation expense																				34,588												34,588
Net loss																								(2,325,618)				(1)				(2,325,619)
Total comprehensive income (loss)																																(2,325,619)
Issued restricted stock (in shares)								10,000
Issued restricted stock								$ 10																								10
Issued stock to 401(k) plan (in shares)								32,651
Issued stock to 401(k) plan								$ 33												39,801												39,834
Issued stock upon exercise of warrants (in shares)								300,595
Issued stock upon exercise of warrants								$ 300												(300)
Deemed dividend on Series C Preferred Stock																				77,778				(77,778)
Issued stock upon conversion of Series C Preferred Stock (in shares)				(70,000)				410,765
Issued stock upon conversion of Series C Preferred Stock				$ (70)				$ 411												(341)
Balance (in shares) at Jun. 30, 2020								24,547,961				461,729
Balance at Jun. 30, 2020								$ 215,545				$ 462								350,178,082				(352,748,108)				731,304				(1,622,715)
Issued restricted stock								$ 10																								10
Unrealized (loss) gain on available-for-sale securities
Issued stock to 401(k) plan (in shares)								32,651

Consolidated Statements of St_2

Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2020USD ($)
Registered Direct Offering [Member]
Stock issuance cost	$ 150,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	1 Months Ended		3 Months Ended				6 Months Ended		12 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net loss			$ (2,325,619)	$ (2,673,608)	$ (2,673,178)	$ (2,429,061)	$ (4,999,227)	$ (5,102,240)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization							36,099	73,505
Stock compensation expense							73,834	128,137
Value of stock issued in payment of employee bonuses							171,522
Value of stock issued in payment of services							4,801
Value of stock issued to 401(k) plan for employer matching contribution							39,834	19,588
Changes in operating assets and liabilities:
Stock subscriptions and other receivables							756,622	(185,712)
Prepaid expenses, right-of-use lease assets, and other assets							837,490	(35,643)
Accounts payable							48,842	248,303
Accrued, lease and other liabilities							(122,442)	91,593
Deferred revenue							166,805	483,976
Net cash used in operating activities							(2,985,820)	(4,278,493)
Cash flows from investing activities:
Proceeds from sales of available-for-sale securities								400,000
Maturities of available-for-sale securities								200,000
(Payments for purchases) proceeds from disposal of equipment							(8,406)	26,875
Patent and trademark costs							(115,271)
Net cash (used in) provided by investing activities							(123,677)	626,875
Cash flows from financing activities:
Proceeds from issuance of preferred stock							700,000
Proceeds from issuance of common stock	$ 812,000	$ 1,900,000					3,025,040	6,046,915	$ 1,100,000
Payment of common stock issuance costs							(150,000)	(572,271)
Proceeds from note payable							366,000
Principal payments on notes payable							(261,701)	(236,050)
Net cash provided by financing activities							3,679,339	5,238,594
Net increase in cash and cash equivalents							569,842	1,586,976
Cash and cash equivalents, beginning of period	$ 1,047,159			$ 1,047,159		$ 3,475,881	1,047,159	3,475,881	3,475,881
Cash and cash equivalents, end of period		$ 1,047,159	$ 1,617,001		$ 5,062,857		$ 1,617,001	$ 5,062,857	$ 1,047,159

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Notes to the Consolidated Financial Statements (unaudited) 1. Summary of Significant Accounting Policies a. Basis of Presentation: June 30, 2020 three six June 30, 2020 2019 June 30, 2020 not December 31, 2019, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. In March 2020, 19 19 19 may not 19. 19 February 2020 2 19 10 19 not b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019, $410,000 $306,000, 8. c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. d. Leases: 2018. 12 not 9. e. Series C Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity, 815, Derivatives and Hedging, 470, Debt 268, Presentation in Financial Statements of "Redeemable Preferred Stocks." not not not 11. f. Recent ly Adopted Accounting Standards : August 2018, No. 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 820. 2018 13 December 15, 2019. 2018 13 not g. Recently Issued Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 : Simplifying the Accounting for Income Taxes 2019 12 2019 12 740 2019 12 December 15, 2020, not 2019 12

Note 2 - Liquidity

Note 2 - Liquidity	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the Company's Annual Report on Form 10 $1.9 10. In addition, the Company is engaged in ongoing litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. See Notes 6 10. The Company has also been engaged in ongoing litigation with Capital Royalty Partners II L.P. (“CRG”) and pursuing recovery of approximately $4.3 November 27, 2019, $4.3 April 9, 2018 ( 10. In February 2020, $4.2 May 6, 2020, 420,000 $4.2 $700,000 second 2020. $3.5 July 1, 2020 10 11 16 In December 2019, 2.1 $1.9 $1.1 2019. $812,000 January 2020. 11. In February 2020, two 4.0 $3.4 $3.0 first second 2020. $392,000 July 2020. 11 16 Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its two 2b 3 Tc99m The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020. 7 May 18, 2020, $366,000 100% During the ongoing COVID- 19 not 19. February 2020 19 10 The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The February 2020 $7.6 On August 9, 2020, $25 7 one not 15 twelve 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3 . Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 not May 11, 2020, Tc99m The Company also has an agreement in place to provide Meilleur Technologies, Inc., (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract's transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company's contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no The sublicense of NAV4694 No. 606, Revenue from Contracts with Customers 606” 606 Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three June 30, 2020 2019, $9,000 $16,000. six June 30, 2020 2019, $24,000 $30,000. three six June 30, 2020 2019, not The following table disaggregates the Company's revenue from contracts with customers for the three six June 30, 2020 2019. Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Royalty revenue: Europe $ 8,920 $ 5,940 $ 24,141 $ 9,090 License revenue: NAV4694 sublicense $ — $ 9,953 $ — $ 9,953 Other revenue: Additional stability studies $ — $ — $ — $ 11,024 The following economic factors affect the nature, amount, timing and uncertainty of the Company's revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through June 30, 2020, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three six June 30, 2020 2019. Three Months Ended June 30, Six Months Ended June 30, 20 20 201 9 20 20 201 9 Total deferred revenue, beginning of period $ 700,000 $ 700,000 $ 700,000 $ 711,024 Revenue deferred related to sublicense 160,000 495,000 160,000 495,000 Revenue recognized from satisfaction of performance obligations — — — (11,024 ) Total deferred revenue, end of period $ 860,000 $ 1,195,000 $ 860,000 $ 1,195,000 The Company had trade receivables of approximately $0 June 30, 2020 December 31, 2019. In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. ASC 606 not 606. 606 not On May 11, 2020 ( March 5, 2015 ( Tc99m Pursuant to the Termination Agreement, the parties agreed that neither owed the other any payments due under the License Agreement as of the Termination Date and that, among other things, SpePharm will no six

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	4 . Stock-Based Compensation For the three June 30, 2020 2019, $35,000 $66,000, six June 30, 2020 2019, $74,000 $128,000, not three six June 30, 2020 2019. A summary of the status of our stock options as of June 30, 2020, six Six Months Ended June 30 , 20 20 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at beginning of period 238,470 $ 17.38 7.2 $ — Granted 195,000 1.06 Exercised — — Canceled and Forfeited (1,500 ) 1.06 Expired (500 ) 30.80 Outstanding at end of period 431,470 $ 10.04 8.0 $ 593,250 Exercisable at end of period 114,870 $ 25.20 5.5 $ 6,768 A summary of the status of our unvested restricted stock as of June 30, 2020, six Six Months Ended June 30 , 20 20 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 15,000 $ 2.75 Granted 10,000 1.06 Vested (15,000 ) 2.75 Forfeited — — Unvested at end of period 10,000 $ 1.06 As of June 30, 2020, $118,000 1.4

Note 5 - Loss Per Share

Note 5 - Loss Per Share	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	5 . Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the six June 30, 2020 2019 1,106,744 1,495,948 The Company's unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 10,000 15,000 six June 30, 2020 2019,

Note 6 - Investment in Macropha

Note 6 - Investment in Macrophage Therapeutics, Inc.	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	6 . Investment in Macrophage Therapeutics, Inc. In August 2018, one February 2019, may New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not August 2018 The Court also rejected Dr. Goldberg's claim for wrongful termination as Chief Executive Officer of MT. In addition, the Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT's Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found the Company's breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 27, 2020, July 9, 2020, 1 2 3 4 July 23, 2020 On January 31, 2020, April 1, 2020, July 31, 2020, 19 Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 December 2020. Derivative Action Involving Dr. Goldberg On July 26, 2019, November 20, 2019, April 3, 2020, 2 10.

Note 7 - Accounts Payable, Accr

Note 7 - Accounts Payable, Accrued Liabilities and Other	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7 . Accounts Payable , Accrued Liabilities and Other Accounts payable as of June 30, 2020 December 31, 2019 $65,000 June 30, 2020 December 31, 2019 $606,000 $925,000,

Note 8 - Notes Payable

Note 8 - Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	8 . Notes Payable IPFS Corporation In November 2018, $393,000 5.1%. ten $40,000, August 2019. Interest expense related to the IPFS note payable totaled $2,000 $6,000 three six June 30, 2019, First Insurance Funding In November 2019, $349,000 5.0%. eight $44,000, July 2020. Interest expense related to the FIF note payable totaled $2,000 $5,000 three six June 30, 2020, $44,000 $306,000 June 30, 2020 December 31, 2019, Payroll Protection Program The CARES Act was enacted on March 27, 2020. 7 May 18, 2020, $366,000. eight twenty-four 100% 1% not seven two Summary During the three June 30, 2020 2019, $2,000 six June 30, 2020 2019, $5,000 $6,000,

Note 9 - Leases

Note 9 - Leases	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	9. Leases We currently lease approximately 5,000 4995 $3,000. June 2023. We also leased approximately 2,000 560 $3,000. March 31, 2019 not In addition, we currently lease approximately 25,000 5600 $27,000 2020. October 2022 five not June 2017, $39,000 October 2022. We also currently lease a vehicle at a monthly payment of approximately $300, September 2021, $100, October 2024. Total operating lease expense was $50,000 $55,000 three June 30, 2020 2019, $102,000 $121,000 six June 30, 2020 2019, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating leases as of June 30, 2020. Maturity of Lease Liabilities Operating Lease Payments 2020 (remaining) $ 157,273 2021 344,552 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 813,990 Less imputed interest 102,301 Present value of operating lease liabilities $ 711,689 Balance Sheet Classification Current lease liabilities $ 277,365 Noncurrent lease liabilities 434,324 Total operating lease liabilities $ 711,689 Other Information Weighted-average remaining lease term for operating leases (in years) 2.4 Weighted-average discount rate for operating leases 10.9 % Cash paid for amounts included in the present value of operating lease liabilities was $181,000 $185,000 six June 30, 2020 2019,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 0 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies not CRG Litigation As disclosed in the Company's Annual Report on Form 10 December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, $7.1 414 $4.1 $59.0 The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio related to Navidea's claims that the Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the Lenders in connection with the Global Settlement Agreement reached in 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 $4.3 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020. may 19 CRG filed another lawsuit in the Texas Court in April 2018. not $7.1 414 2. Platinum Li tigation In November 2017, $1.9 March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not April 28, 2020 19 not June 4, 2020. September 8, 2020. 2. Goldberg Agreement and Litigation In August 2018, one 1,175,000 1,175,000 18 5% November 2018, 925,000 250,000 On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg's claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT's Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found Navidea's breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 27, 2020, July 9, 2020, 1 2 3 4 July 23, 2020 On January 31, 2020, April 1, 2020, July 31, 2020, 19 Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 December 2020. Derivative Action Involving Dr. Goldberg On July 26, 2019, November 20, 2019, April 3, 2020, 2 6. NYSE American Continued Listing Standards On August 14, 2018, not not 1003 $6.0 five 1003 The Company regained compliance with the minimum trading price standard following a one twenty April 26, 2019. On February 14, 2020, $6.0 1003 19 $1.6 June 30, 2020. Even if an issuer has a stockholders' deficit, the NYSE American will not 1 $50,000,000; $50,000,000 two three 2 1,100,000 $15,000,000 400 June 30, 2020, $96.7 not may

Note 11 - Equity

Note 11 - Equity	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 1 . Equity In December 2019, 2.1 $1.9 $1.1 2019. $812,000 January 2020. $812,000 December 31, 2019. In February 2020, two 4.0 $3.4 $3.0 first second 2020. $392,000 July 2020. $392,000 June 30, 2020. Also in February 2020, $4.3 $4.2 May 6, 2020, 420,000 $4.2 one November 6, 2020, Holders of the Series C Preferred Stock may 10% may not 19.99% not not $11 In the event of the liquidation or dissolution of the Company, after payment of the debts and other liabilities of the Company, the holders of Series C Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company and before any payment may x Of the $4.2 $700,000 70,000 second 2020. 70,000 410,765 second 2020. $3.5 350,000 July 1, 2020 10 350,000 1,014,311 July 1, 2020 10 $3.5 June 30, 2020. In accordance with current accounting guidance, the Company recorded a deemed dividend of approximately $78,000 70,000 three June 30, 2020. 1 Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its two 2b 3 Tc99m 2. During the six June 30, 2020, 94,159 $172,000 2019 During the six June 30, 2020 2019, 32,651 8,128 401 $40,000 $20,000,

Note 12 - Stock Warrants

Note 12 - Stock Warrants	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 2 . Stock Warrants In May 2020, 411,000 300,595 As of June 30, 2020, 991,874 $0.20 $49.80 $18.37 one 15.1

Note 13 - Income Taxes

Note 13 - Income Taxes	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 3 . Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not June 30, 2020 December 31, 2019, In assessing the realizability of DTAs, management considers whether it is more likely than not not not not June 30, 2020, The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. 2018, 2019 2020. may 2018 2020, 50% 2018, 2019 2020 2021. $621,000 December 31, 2019, 50% 50% December 31, 2019. March 27, 2020. 100% 2018 $621,000 second 2020. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no June 30, 2020 December 31, 2019 not twelve June 30, 2020, 2016 2019 As of June 30, 2020, $142.2 $20.1 $8.8

Note 14 - Segments

Note 14 - Segments	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 4 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two Tc99m NAV4694 April 2018), The information in the following tables is derived directly from each reportable segment's financial reporting. T hree Months Ended June 30 , 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 8,920 $ — $ — $ 8,920 Grant and other revenue 215,458 46,723 — 262,181 Total revenue 224,378 46,723 — 271,101 Cost of revenue 357 — — 357 Research and development expenses 1,193,151 88,628 — 1,281,779 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 972 1,309,363 1,310,335 Depreciation and amortization (2) — — 19,256 19,256 Loss from operations (3) (969,130 ) (42,877 ) (1,328,619 ) (2,340,626 ) Other income (4) — — 15,007 15,007 Net loss (969,130 ) (42,877 ) (1,313,612 ) (2,325,619 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 1,947 1,947 T hree Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 5,940 $ — $ — $ 5,940 License revenue 9,953 — — 9,953 Grant and other revenue 196,630 47,569 — 244,199 Total revenue 212,523 47,569 — 260,092 Cost of revenue 238 — — 238 Research and development expenses 775,462 295,180 — 1,070,642 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,062 1,821,812 1,824,874 Depreciation and amortization (2) — — 36,726 36,726 Loss from operations (3) (563,177 ) (250,673 ) (1,858,538 ) (2,672,388 ) Other expense (4) — — (1,590 ) (1,590 ) Income tax benefit 35 16 117 168 Net loss from continuing operations (563,142 ) (250,657 ) (1,860,011 ) (2,673,810 ) Income from discontinued operations, net of tax 632 — — 632 Net loss (562,510 ) (250,657 ) (1,860,011 ) (2,673,178 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 Six Months Ended June 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 24,141 $ — $ — $ 24,141 Grant and other revenue 274,374 128,858 — 403,232 Total revenue 298,515 128,858 — 427,373 Cost of revenue 966 — — 966 Research and development expenses 2,150,777 130,271 — 2,281,048 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 3,121,796 3,121,246 Depreciation and amortization (2) — — 36,099 36,099 Loss from operations (3) (1,853,228 ) (863 ) (3,157,895 ) (5,011,986 ) Other income (4) — — 12,759 12,759 Net loss (1,853,228 ) (863 ) (3,145,136 ) (4,999,227 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 8,406 8,406 Six Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,090 $ — $ — $ 9,090 License revenue 9,953 — — 9,953 Grant and other revenue 232,621 50,052 — 282,673 Total revenue 251,664 50,052 — 301,716 Cost of revenue 6,364 — — 6,364 Research and development expenses 1,516,045 295,180 — 1,811,225 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 14,776 3,501,835 3,516,611 Depreciation and amortization (2) — — 73,505 73,505 Loss from operations (3) (1,270,745 ) (259,904 ) (3,575,340 ) (5,105,989 ) Other income (4) — — 7,122 7,122 Provision for income tax (177 ) (36 ) (495 ) (708 ) Net loss from continuing operations (1,270,922 ) (259,940 ) (3,568,713 ) (5,099,575 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (1,273,587 ) (259,940 ) (3,568,713 ) (5,102,240 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization is reflected in selling, general and administrative expenses ( $19,256 $36,726 three June 30, 2020 2019, $36,099 $73,505 six June 30, 2020 2019, ( 3 Loss from operations does not ( 4 Amounts consist primarily of interest income and interest expense, which are not

Note 15 - Supplemental Disclosu

Note 15 - Supplemental Disclosure for Statements of Cash Flows	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	1 5 . Supplemental Disclosure for Statements of Cash Flows During the six June 30, 2020 2019, $5,000 $6,000, six June 30, 2020, 94,159 $172,000 2019 six June 30, 2020 2019, 32,651 8,128 401 $40,000 $20,000, six June 30, 2020, 411,000 300,595 six June 30, 2020, $78,000 70,000 70,000 410,765

Note 16 - Subsequent Events

Note 16 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	1 6 . Subsequent Events The Company has evaluated events and transactions subsequent to June 30, 2020 10 a. Preferred Stock: May 6, 2020, 420,000 $4.2 $700,000 70,000 second 2020. 70,000 410,765 second 2020. $3.5 350,000 July 1, 2020 10 350,000 1,014,311 July 1, 2020 10 2 11. b. Common Stock: February 2020, two 4.0 $3.4 $3.0 first 2020. $392,000 July 2020. $392,000 June 30, 2020. 2 11. c. Private Placement Commitment: August 9, 2020 $25.0 The Commitment Letter requires the Sponsor to purchase, or cause the purchase of, shares of Navidea's common stock, and to pay, or cause to be paid, to Navidea funds an aggregate cash purchase of up to $25.0 not may one 7 one not 15 This Commitment Letter and the obligation of the Sponsor to fund the Equity Commitment will terminate automatically and immediately upon the earliest to occur of (a) the mutual agreement of the Sponsor and Navidea, and (b) the closing, at which time such obligation will be discharged but subject to the performance of such obligation. In addition, Navidea may not d. Memorandum of Understanding: August 9, 2020, , Tc99m In connection with the MOU, the company entered into a Stock Purchase Agreement with Jubilant (the "Jubilant Stock Purchase Agreement"), pursuant to which Jubilant agreed to purchase $1.0 The MOU outlines certain terms that are expected to be included in the ELDA, including: ● Jubilant to provide Navidea with an addition $19.0 NAV3 32 2b NAV3 33 3 ● Jubilant will pay license fees and sales-based royalties to Navidea based on revenue generated from the sale of TRA in the licensed territory. ● Jubilant will serve as the exclusive commerical and distribution partner for TRA in the United States, Canada, Mexico, and Latin America. Jubilant will be responsible for all commercialization efforts within the licensed territory. The execution of the ELDA is subject to certain conditions, including negotiation of a definitive agreement in mutually acceptable form and Jubilant's completion of its due diligence.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: June 30, 2020 three six June 30, 2020 2019 June 30, 2020 not December 31, 2019, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. In March 2020, 19 19 19 may not 19. 19 February 2020 2 19 10 19 not
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019, $410,000 $306,000, 8.
Revenue [Policy Text Block]	c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
Lessee, Leases [Policy Text Block]	d. Leases: 2018. 12 not 9.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	e. Series C Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity, 815, Derivatives and Hedging, 470, Debt 268, Presentation in Financial Statements of "Redeemable Preferred Stocks." not not not 11.
New Accounting Pronouncements, Policy [Policy Text Block]	f. Recent ly Adopted Accounting Standards : August 2018, No. 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 820. 2018 13 December 15, 2019. 2018 13 not g. Recently Issued Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 : Simplifying the Accounting for Income Taxes 2019 12 2019 12 740 2019 12 December 15, 2020, not 2019 12

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Royalty revenue: Europe $ 8,920 $ 5,940 $ 24,141 $ 9,090 License revenue: NAV4694 sublicense $ — $ 9,953 $ — $ 9,953 Other revenue: Additional stability studies $ — $ — $ — $ 11,024
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 20 20 201 9 20 20 201 9 Total deferred revenue, beginning of period $ 700,000 $ 700,000 $ 700,000 $ 711,024 Revenue deferred related to sublicense 160,000 495,000 160,000 495,000 Revenue recognized from satisfaction of performance obligations — — — (11,024 ) Total deferred revenue, end of period $ 860,000 $ 1,195,000 $ 860,000 $ 1,195,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Six Months Ended June 30 , 20 20 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at beginning of period 238,470 $ 17.38 7.2 $ — Granted 195,000 1.06 Exercised — — Canceled and Forfeited (1,500 ) 1.06 Expired (500 ) 30.80 Outstanding at end of period 431,470 $ 10.04 8.0 $ 593,250 Exercisable at end of period 114,870 $ 25.20 5.5 $ 6,768
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Six Months Ended June 30 , 20 20 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 15,000 $ 2.75 Granted 10,000 1.06 Vested (15,000 ) 2.75 Forfeited — — Unvested at end of period 10,000 $ 1.06

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2020 (remaining) $ 157,273 2021 344,552 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 813,990 Less imputed interest 102,301 Present value of operating lease liabilities $ 711,689
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 277,365 Noncurrent lease liabilities 434,324 Total operating lease liabilities $ 711,689
Lease, Cost [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (in years) 2.4 Weighted-average discount rate for operating leases 10.9 %

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	T hree Months Ended June 30 , 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 8,920 $ — $ — $ 8,920 Grant and other revenue 215,458 46,723 — 262,181 Total revenue 224,378 46,723 — 271,101 Cost of revenue 357 — — 357 Research and development expenses 1,193,151 88,628 — 1,281,779 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 972 1,309,363 1,310,335 Depreciation and amortization (2) — — 19,256 19,256 Loss from operations (3) (969,130 ) (42,877 ) (1,328,619 ) (2,340,626 ) Other income (4) — — 15,007 15,007 Net loss (969,130 ) (42,877 ) (1,313,612 ) (2,325,619 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 1,947 1,947 T hree Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 5,940 $ — $ — $ 5,940 License revenue 9,953 — — 9,953 Grant and other revenue 196,630 47,569 — 244,199 Total revenue 212,523 47,569 — 260,092 Cost of revenue 238 — — 238 Research and development expenses 775,462 295,180 — 1,070,642 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,062 1,821,812 1,824,874 Depreciation and amortization (2) — — 36,726 36,726 Loss from operations (3) (563,177 ) (250,673 ) (1,858,538 ) (2,672,388 ) Other expense (4) — — (1,590 ) (1,590 ) Income tax benefit 35 16 117 168 Net loss from continuing operations (563,142 ) (250,657 ) (1,860,011 ) (2,673,810 ) Income from discontinued operations, net of tax 632 — — 632 Net loss (562,510 ) (250,657 ) (1,860,011 ) (2,673,178 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514 Six Months Ended June 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 24,141 $ — $ — $ 24,141 Grant and other revenue 274,374 128,858 — 403,232 Total revenue 298,515 128,858 — 427,373 Cost of revenue 966 — — 966 Research and development expenses 2,150,777 130,271 — 2,281,048 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 3,121,796 3,121,246 Depreciation and amortization (2) — — 36,099 36,099 Loss from operations (3) (1,853,228 ) (863 ) (3,157,895 ) (5,011,986 ) Other income (4) — — 12,759 12,759 Net loss (1,853,228 ) (863 ) (3,145,136 ) (4,999,227 ) Total assets, net of depreciation and amortization: United States $ 107,185 $ 36,483 $ 6,463,015 $ 6,606,683 Capital expenditures — — 8,406 8,406 Six Months Ended June 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,090 $ — $ — $ 9,090 License revenue 9,953 — — 9,953 Grant and other revenue 232,621 50,052 — 282,673 Total revenue 251,664 50,052 — 301,716 Cost of revenue 6,364 — — 6,364 Research and development expenses 1,516,045 295,180 — 1,811,225 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 14,776 3,501,835 3,516,611 Depreciation and amortization (2) — — 73,505 73,505 Loss from operations (3) (1,270,745 ) (259,904 ) (3,575,340 ) (5,105,989 ) Other income (4) — — 7,122 7,122 Provision for income tax (177 ) (36 ) (495 ) (708 ) Net loss from continuing operations (1,270,922 ) (259,940 ) (3,568,713 ) (5,099,575 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (1,273,587 ) (259,940 ) (3,568,713 ) (5,102,240 ) Total assets, net of depreciation and amortization: United States $ 220,334 $ 11,235 $ 7,892,312 $ 8,123,881 International 6,514 — — 6,514

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Notes Payable, Fair Value Disclosure	$ 410,000	$ 306,000

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	May 18, 2020	May 06, 2020	Nov. 27, 2019	Aug. 13, 2020	Jul. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Nov. 30, 2017	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues (in shares)								2,100,000
Stock Issued During Period, Value, New Issues													$ 5,166,441	$ 50,000
Proceeds from Issuance of Preferred Stock and Preference Stock															$ 700,000
Proceeds from Issuance of Common Stock							$ 812,000	$ 1,900,000							3,025,040	6,046,915	$ 1,100,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable											$ 392,000				392,000
Proceeds from Notes Payable, Total															366,000
Increase in Additional Working Capital						$ 7,600,000
Forecast [Member]
Increase in Additional Working Capital										$ 25
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 366,000
Investor [Member]
Litigation Settlement, Amount Awarded from Other Party						$ 4,300,000
Stock Issued During Period, Shares, New Issues (in shares)						4,000,000
Proceeds from Issuance of Common Stock						$ 3,400,000									3,000,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable											$ 392,000				$ 392,000
Accounts and Other Receivables [Member]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable								$ 812,000									$ 812,000
Subsequent Event [Member]
Proceeds from Issuance of Common Stock					$ 392,000
Subsequent Event [Member] | Investor [Member]
Proceeds from Issuance of Common Stock					$ 392,000
Series C Preferred Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)				350,000
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 3,500,000
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		420,000				420,000					70,000
Stock Issued During Period, Value, New Issues		$ 4,200,000				$ 4,200,000
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 700,000									$ 700,000
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member] | Subsequent Event [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 3,500,000
Platinum-Montaur Life Sciences LLC Litigation [Member]
Loss Contingency, Damages Sought, Value									$ 1,900,000
CRG Loan Agreement, Ohio Case [Member]
Loss Contingency, Damages Sought, Value												$ 4,300,000
Ohio Court of Common Pleas [Member]
Litigation Settlement, Amount Awarded from Other Party			$ 4,300,000
Proceeds From Sale Of Judgment						$ 4,200,000

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Contract with Customer, Payment Term, Minimum (Day)		15 days
Contract with Customer, Payment Term, Maximum (Day)		90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method		$ 0
Revenue from Contract with Customer, Including Assessed Tax	$ 9,000		$ 16,000		$ 24,000	$ 30,000
Contract with Customer, Asset, Impairment Loss		$ 0		$ 0	0	$ 0
Capitalized Contract Cost, Net, Total	0				0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	$ 0				$ 0		$ 0
INDIA
Contract with Customer, Term of Contract (Year)		8 years
CHINA
Contract with Customer, Term of Contract (Year)		10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue from contract with customer	$ 9,000	$ 16,000	$ 24,000	$ 30,000
Royalty [Member]
Revenue from contract with customer	8,920	5,940	24,141	9,090
Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	8,920	5,940	24,141	9,090
NAV4694 Sublicense [Member] | Diagnostics Segment [Member]
Revenue from contract with customer		9,953		9,953
Product and Service, Other [Member] | Diagnostics Segment [Member]
Revenue from contract with customer				11,024
Europe [Member] | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	$ 8,920	$ 5,940	$ 24,141	$ 9,090

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total deferred revenue, beginning of period	$ 700,000	$ 700,000	$ 700,000	$ 711,024
Revenue deferred related to sublicense	160,000	495,000	160,000	495,000
Revenue recognized from satisfaction of performance obligations				(11,024)
Total deferred revenue, end of period	$ 860,000	$ 1,195,000	$ 860,000	$ 1,195,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expense	$ 35,000	$ 66,000	$ 74,000	$ 128,000
Share-based Payment Arrangement, Expense, Tax Benefit	0	$ 0	0	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 118,000		$ 118,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 146 days

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Outstanding at beginning of period (in shares) | shares	238,470
Outstanding at beginning of period, weighted average exercise price (in dollars per share) | $ / shares	$ 17.38
Granted (in shares) | shares	195,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 1.06
Exercised (in shares) | shares
Exercised, weighted average exercise price (in dollars per share) | $ / shares
Canceled and Forfeited (in shares) | shares	(1,500)
Canceled and Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 1.06
Expired (in shares) | shares	(500)
Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 30.80
Outstanding at end of period (in shares) | shares	431,470
Outstanding at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 10.04
Outstanding at end of period (Year)	8 years
Outstanding at end of period | $	$ 593,250
Exercisable at end of period (in shares) | shares	114,870
Exercisable at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 25.20
Exercisable at end of period (Year)	5 years 182 days
Exercisable at end of period | $	$ 6,768

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Unvested at beginning of period (in shares) | shares	15,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.75
Granted (in shares) | shares	10,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.06
Vested (in shares) | shares	(15,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.75
Forfeited (in shares) | shares
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares
Unvested at end of period (in shares) | shares	10,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.06

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,106,744	1,495,948
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	10,000	15,000

Note 7 - Accounts Payable, Ac_2

Note 7 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - Director Fees [Member] - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accounts Payable [Member]
Due to Related Parties, Current, Total	$ 65,000	$ 65,000
Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 606,000	$ 925,000

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual)	May 18, 2020USD ($)	Nov. 30, 2019USD ($)	Nov. 30, 2018USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	May 31, 2015
Interest Expense, Debt, Total				$ 2,000	$ 2,000	$ 5,000	$ 6,000
Notes Payable, Current, Total				410,254		410,254		$ 305,955
Proceeds from Notes Payable, Total						366,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount			$ 393,000
Debt Instrument, Interest Rate, Stated Percentage			5.10%
Debt Instrument, Term (Month)			300 days
Debt Instrument, Periodic Payment, Total			$ 40,000
Interest Expense, Debt, Total					$ 2,000		$ 6,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount		$ 349,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Term (Month)		240 days
Debt Instrument, Periodic Payment, Total		$ 44,000
Interest Expense, Debt, Total				2,000		5,000
Notes Payable, Current, Total				$ 44,000		$ 44,000		$ 306,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 366,000
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument, Number of Quarterly Payments									8

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended			6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)ft²	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)
Operating Lease, Expense		$ 50,000	$ 55,000		$ 102,000	$ 121,000
Operating Lease, Payments					$ 181,000	$ 185,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		5,000			5,000
Operating Lease, Monthly Base Rent					$ 3,000
Office Space at 560 Sylvan Avenue, Englewood Cliffs, New Jersey [Member]
Area of Real Estate Property (Square Foot) | ft²				2,000
Operating Lease, Monthly Base Rent				$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		25,000			25,000
Operating Lease, Monthly Base Rent					$ 27,000
Lessee, Operating Lease, Renewal Term (Year)		5 years			5 years
Operating Lease, Sublease, Monthly Rent Revenue	$ 39,000
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent					$ 300
Office Equipment [Member]
Operating Lease, Monthly Base Rent					$ 100

Note 9 - Leases - Maturity of L

Note 9 - Leases - Maturity of Lease Liabilities (Details)	Jun. 30, 2020USD ($)
2020 (remaining)	$ 157,273
2021	344,552
2022	291,111
2023	19,699
2024	1,355
Total undiscounted operating lease payments	813,990
Less imputed interest	102,301
Present value of operating lease liabilities	$ 711,689

Note 9 - Leases - Balance Sheet

Note 9 - Leases - Balance Sheet Classification (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current lease liabilities	$ 277,365	$ 250,553
Noncurrent lease liabilities	434,324	$ 512,344
Present value of operating lease liabilities	711,689
Other Current Liabilities [Member]
Current lease liabilities	277,365
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 434,324

Note 9 - Leases - Other Informa

Note 9 - Leases - Other Information (Details)	Jun. 30, 2020
Weighted-average remaining lease term for operating leases (in years) (Year)	2 years 146 days
Weighted-average discount rate for operating leases	10.90%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual)

Nov. 27, 2019USD ($)

Apr. 26, 2019

Aug. 14, 2018

Apr. 09, 2018USD ($)

Nov. 02, 2017USD ($)

Mar. 03, 2017USD ($)

Dec. 31, 2019USD ($)shares

Nov. 30, 2018shares

Nov. 30, 2017USD ($)

Jun. 30, 2016USD ($)

Jun. 30, 2019USD ($)shares

Mar. 31, 2019USD ($)shares

Jun. 30, 2020USD ($)

Mar. 31, 2020USD ($)

Feb. 14, 2020USD ($)

Dec. 31, 2018USD ($)

Aug. 31, 2018shares

Stock Issued During Period, Shares, New Issues (in shares) | shares

2,100,000

Stockholders' Equity Attributable to Parent, Ending Balance

$ (1,612,292)

$ (2,354,019)

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

(880,989)

$ 2,931,507

$ 94,635

(1,622,715)

$ (1,091,039)

$ 2,410,460

Market Capitalization, Fair Value

96,700,000

Pro Forma [Member]

Stockholders' Equity Attributable to Parent, Ending Balance

$ 6,000,000

Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares) | shares

8,000,000

17,857

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 210,232

$ 209,056

$ 201,048

$ 215,545

$ 212,191

$ 200,391

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement (in shares) | shares

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period (Month)

1 year 180 days

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares) | shares

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares) | shares

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5.00%

CRG [Member]

Draws on Letter of Credit

$ 7,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Maximum [Member] | Before Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

59,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual) - USD ($)	May 06, 2020	Aug. 13, 2020	Jul. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues (in shares)						2,100,000
Proceeds from Issuance of Common Stock					$ 812,000	$ 1,900,000					$ 3,025,040	$ 6,046,915	$ 1,100,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable							$ 392,000				392,000
Stock Issued During Period, Value, New Issues									$ 5,166,441	$ 50,000
Proceeds from Issuance of Preferred Stock and Preference Stock											$ 700,000
Stock Issued During Period, Value, Issued for Services								$ 4,801
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)											32,651	8,128
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution											$ 39,834	$ 19,588
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)									8,000,000	17,857
Stock Issued During Period, Value, New Issues									$ 8,000	$ 357
Stock Issued During Period, Shares, Issued for Services (in shares)								3,810
Stock Issued During Period, Value, Issued for Services								$ 4
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)							40,844	53,315
Conversion from Series C Preferred Stock To Common Stock [Member]
Stock Issued During Period, Value, New Issues							$ 700,000
Conversion of Stock, Shares Converted (in shares)							70,000				70,000
Conversion of Stock, Shares Issued (in shares)							410,765				410,765
Conversion from Series C Preferred Stock To Common Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)
Stock Issued During Period, Value, New Issues
Series C Preferred Stock [Member]
Preferred Stock, Deemed Dividend							$ 78,000				$ 78,000
Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	420,000			420,000			70,000
Stock Issued During Period, Value, New Issues	$ 4,200,000			$ 4,200,000
Convertible Preferred Stock, Discount to Market Rate				10.00%
Convertible Preferred Stock, Maximum Allowed Percentage of Common Stock Outstanding Used in Conversion Shares				19.99%
Convertible Preferred Stock, Share Price upon Conversion if Exchange Cap is Reached (in dollars per share)							$ 11				$ 11
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 700,000						$ 700,000
Subsequent Event [Member]
Proceeds from Issuance of Common Stock			$ 392,000
Subsequent Event [Member] | Conversion from Series C Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)		350,000
Conversion of Stock, Shares Issued (in shares)		1,014,311
Subsequent Event [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		350,000
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 3,500,000
Subsequent Event [Member] | Keystone Capital Partners, LLC [Member] | Series C Preferred Stock [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 3,500,000
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)				4,000,000
Proceeds from Issuance of Common Stock				$ 3,400,000							$ 3,000,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable							392,000				$ 392,000
Litigation Settlement, Amount Awarded from Other Party				4,300,000
Litigation Settlement, Sales Price				$ 4,200,000
Investor [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock			$ 392,000
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)											94,159
Stock Issued During Period, Value, Issued for Services											$ 172,000
Prepaid Expenses and Other Current Assets [Member]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable						$ 812,000							$ 812,000
Stock Subscriptions and Other Receivables [Member]
Stock Subscriptions Receivable							$ 3,500,000				$ 3,500,000

Note 12 - Stock Warrants (Detai

Note 12 - Stock Warrants (Details Textual) - $ / shares	1 Months Ended	6 Months Ended
	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Class of Warrant or Right, Outstanding (in shares)		991,874
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 18.37
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.20
Warrants and Rights Outstanding, Term (Year)		1 year
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 49.80
Warrants and Rights Outstanding, Term (Year)		15 years 36 days
Series OO Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)	411,000		411,000
Issued Stock Upon Exercise of Warrants, Shares (in shares)	300,595	300,595

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Included in Prepaid and Other Current Assets		50.00%
Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Included in Other Noncurrent Assets		50.00%
Unrecognized Tax Benefits, Ending Balance	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	142,200,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	20,100,000
Alternative Minimum Tax [Member]
Tax Credit Carryforward, Amount		$ 621,000
Alternative Minimum Tax [Member] | Prepaid Expenses and Other Current Assets [Member]
Tax Credit Carryforward, Amount	621,000
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Amount	$ 8,800,000

Note 14 - Segments (Details Tex

Note 14 - Segments (Details Textual)		3 Months Ended			6 Months Ended
		Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Revenues, Total		$ 271,101		$ 260,092	$ 427,373	$ 301,716
Number of Primary Types of Products Sold		2			2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 19,256		36,726	$ 36,099	73,505
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		$ 19,256		$ 36,726	$ 36,099	$ 73,505
Intersegment Eliminations [Member]
Revenues, Total			$ 0
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($19,256 and $36,726 for the three-month periods ended June 30, 2020 and 2019, and $36,099 and $73,505 for the six-month periods ended June 30, 2020 and 2019, respectively).

Note 14 - Segments - Segment In

Note 14 - Segments - Segment Information (Details) - USD ($)		3 Months Ended				6 Months Ended
		Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Revenue from contract with customer		$ 9,000		$ 16,000		$ 24,000	$ 30,000
Grant and other revenue		262,181		244,199		403,232	282,673
Revenues, Total		271,101		260,092		427,373	301,716
Cost of revenue		357		238		966	6,364
Research and development expenses		1,281,779		1,070,642		2,281,048	1,811,225
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,310,335		1,824,874		3,121,246	3,516,611
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	19,256		36,726		36,099	73,505
Loss from operations (3)	[3]	(2,340,626)		(2,672,388)		(5,011,986)	(5,105,989)
Other income (4)	[4]	15,007		(1,590)		12,759	7,122
Net loss		(2,325,619)	$ (2,673,608)	(2,673,178)	$ (2,429,061)	(4,999,227)	(5,102,240)
Total assets, net of depreciation and amortization		7,106,683				7,106,683		$ 4,150,906
Capital expenditures		1,947				8,406
Revenue from contract with customer		9,000		16,000		24,000	30,000
Loss from operations (3)	[3]	(2,340,626)		(2,672,388)		(5,011,986)	(5,105,989)
Other expense (4)	[4]	15,007		(1,590)		12,759	7,122
Income tax benefit				168			(708)
Net loss from continuing operations				(2,673,810)			(5,099,575)
Income from discontinued operations, net of tax				632			(2,665)
Total assets, net of depreciation and amortization:		7,106,683				7,106,683		$ 4,150,906
UNITED STATES
Total assets, net of depreciation and amortization		6,606,683		8,123,881		6,606,683	8,123,881
Total assets, net of depreciation and amortization:		6,606,683		8,123,881		6,606,683	8,123,881
Non-US [Member]
Total assets, net of depreciation and amortization				6,514			6,514
Total assets, net of depreciation and amortization:				6,514			6,514
Royalty [Member]
Revenue from contract with customer		8,920		5,940		24,141	9,090
Revenue from contract with customer		8,920		5,940		24,141	9,090
License [Member]
Revenue from contract with customer				9,953			9,953
Revenue from contract with customer				9,953			9,953
Diagnostics Segment [Member]
Grant and other revenue		215,458		196,630		274,374	232,621
Revenues, Total		224,378		212,523		298,515	251,664
Cost of revenue		357		238		966	6,364
Research and development expenses		1,193,151		775,462		2,150,777	1,516,045
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations (3)	[3]	(969,130)		(563,177)		(1,853,228)	(1,270,745)
Other income (4)	[4]
Net loss		(969,130)		(562,510)		(1,853,228)	(1,273,587)
Capital expenditures
Loss from operations (3)	[3]	(969,130)		(563,177)		(1,853,228)	(1,270,745)
Other expense (4)	[4]
Income tax benefit				35			(177)
Net loss from continuing operations				(563,142)			(1,270,922)
Income from discontinued operations, net of tax				632			(2,665)
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		107,185		220,334		107,185	220,334
Total assets, net of depreciation and amortization:		107,185		220,334		107,185	220,334
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization				6,514			6,514
Total assets, net of depreciation and amortization:				6,514			6,514
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		8,920		5,940		24,141	9,090
Revenue from contract with customer		8,920		5,940		24,141	9,090
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer				9,953			9,953
Revenue from contract with customer				9,953			9,953
Therapeutics Segment [Member]
Grant and other revenue		46,723		47,569		128,858	50,052
Revenues, Total		46,723		47,569		128,858	50,052
Cost of revenue
Research and development expenses		88,628		295,180		130,271	295,180
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	972		3,062		(550)	14,776
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations (3)	[3]	(42,877)		(250,673)		(863)	(259,904)
Other income (4)	[4]
Net loss		(42,877)		(250,657)		(863)	(259,940)
Capital expenditures
Loss from operations (3)	[3]	(42,877)		(250,673)		(863)	(259,904)
Other expense (4)	[4]
Income tax benefit				16			(36)
Net loss from continuing operations				(250,657)			(259,940)
Income from discontinued operations, net of tax
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		36,483		11,235		36,483	11,235
Total assets, net of depreciation and amortization:		36,483		11,235		36,483	11,235
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Total assets, net of depreciation and amortization:
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer
Revenue from contract with customer
Corporate Segment [Member]
Grant and other revenue
Revenues, Total
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,309,363		1,821,812		3,121,796	3,501,835
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	19,256		36,726		36,099	73,505
Loss from operations (3)	[3]	(1,328,619)		(1,858,538)		(3,157,895)	(3,575,340)
Other income (4)	[4]	15,007		(1,590)		12,759	7,122
Net loss		(1,313,612)		(1,860,011)		(3,145,136)	(3,568,713)
Capital expenditures		1,947				8,406
Loss from operations (3)	[3]	(1,328,619)		(1,858,538)		(3,157,895)	(3,575,340)
Other expense (4)	[4]	15,007		(1,590)		12,759	7,122
Income tax benefit				117			(495)
Net loss from continuing operations				(1,860,011)			(3,568,713)
Income from discontinued operations, net of tax
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		6,463,015		7,892,312		6,463,015	7,892,312
Total assets, net of depreciation and amortization:		6,463,015		7,892,312		6,463,015	7,892,312
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Total assets, net of depreciation and amortization:
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer
Revenue from contract with customer
Corporate Segment [Member] | License [Member]
Revenue from contract with customer
Revenue from contract with customer
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($19,256 and $36,726 for the three-month periods ended June 30, 2020 and 2019, and $36,099 and $73,505 for the six-month periods ended June 30, 2020 and 2019, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4]	Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 15 - Supplemental Disclo_2

Note 15 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Interest Paid, Excluding Capitalized Interest, Operating Activities				$ 5,000	$ 6,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)				94,159
Stock Issued During Period, Value, Employee Benefit Plan		$ 39,834	$ 19,588	$ 172,000
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)				32,651	8,128
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution				$ 39,834	$ 19,588
Conversion from Series C Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)		70,000		70,000
Conversion of Stock, Shares Issued (in shares)		410,765		410,765
Series C Preferred Stock [Member]
Preferred Stock, Deemed Dividend		$ 78,000		$ 78,000
Series OO Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)	411,000				411,000
Issued Stock Upon Exercise of Warrants, Shares (in shares)	300,595			300,595

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	May 06, 2020	Aug. 13, 2020	Jul. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Aug. 09, 2020
Stock Issued During Period, Shares, New Issues (in shares)						2,100,000
Stock Issued During Period, Value, New Issues									$ 5,166,441	$ 50,000
Proceeds from Issuance of Preferred Stock and Preference Stock											$ 700,000
Proceeds from Issuance of Common Stock					$ 812,000	$ 1,900,000					3,025,040	$ 6,046,915	$ 1,100,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable							$ 392,000				392,000
Private Placement [Member]
Stock Issued During Period, Value, New Issues							520,030
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)				4,000,000
Proceeds from Issuance of Common Stock				$ 3,400,000							3,000,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable							392,000				$ 392,000
Subsequent Event [Member]
Proceeds from Issuance of Common Stock			$ 392,000
Subsequent Event [Member] | Investor [Member]
Proceeds from Issuance of Common Stock			$ 392,000
Conversion from Series C Preferred Stock To Common Stock [Member]
Stock Issued During Period, Value, New Issues							$ 700,000
Conversion of Stock, Shares Converted (in shares)							70,000				70,000
Conversion of Stock, Shares Issued (in shares)							410,765				410,765
Conversion from Series C Preferred Stock To Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted (in shares)		350,000
Conversion of Stock, Shares Issued (in shares)		1,014,311
Mastiff Group LLC [Member] | Subsequent Event [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount														$ 25,000,000
Jubilant [Member] | Subsequent Event [Member] | Private Placement [Member]
Sale of Stock, Commitment Amount														1,000,000
Sale of Stock, Additional Milestone Commitment Amount														$ 19,000,000
Series C Preferred Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)		350,000
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 3,500,000
Series C Preferred Stock [Member] | Keystone Capital Partners, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)	420,000			420,000			70,000
Stock Issued During Period, Value, New Issues	$ 4,200,000			$ 4,200,000
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 700,000						$ 700,000
Series C Preferred Stock [Member] | Keystone Capital Partners, LLC [Member] | Subsequent Event [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 3,500,000